Stock Research Monitor: LJPC, LXRX, and MNKD
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), and Marinus Pharmaceuticals Inc. (NASDAQ: MRNS). All you have to do is sign up today for this free limited time offer by clicking the link below.
La Jolla Pharmaceutical
On Friday, shares in San Diego, California headquartered La Jolla Pharmaceutical Co. recorded a trading volume of 221,227 shares. The stock ended at $30.49, rising 0.20% from the last trading session. The stock is trading below its 50-day moving average by 1.28%. Furthermore, shares of the Company, which focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases, have a Relative Strength Index (RSI) of 51.99. Get the full research report on LJPC for free by clicking below at:
The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc.'s stock finished last Friday's session 0.56% lower at $12.33. A total volume of 403,768 shares was traded. The Company's shares have gained 52.41% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 7.69% and 21.88%, respectively. Furthermore, shares of Lexicon Pharma, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have an RSI of 50.02. Get access to our top-rated research, including the free report on LXRX at:
At the close of trading on Friday, shares in Westlake Village, California headquartered MannKind Corp. saw a decline of 4.49%, ending the day at $1.70. The stock recorded a trading volume of 1.32 million shares. The Company's shares have advanced 28.79% over the last twelve months. The stock is trading below its 50-day moving average by 10.13%. Moreover, shares of MannKind, which focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients, have an RSI of 36.10. Click here to subscribe for a free membership which welcomes you with our report on MNKD at:
Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc.'s shares ended the day 4.49% higher at $8.14 with a total trading volume of 421,913 shares. The stock has gained 12.12% in the last month, 71.01% in the previous three months, and 507.46% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 28.15% and 32.71%, respectively. Additionally, shares of Marinus Pharma, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have an RSI of 66.48.
On July 02nd, 2018, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $19 per share. To get free access to your research report on MRNS, sign up at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities